Minerva endocrinology最新文献

筛选
英文 中文
Microdosing, fractional and split dosing of injectable GLP-1-based drugs: balancing potential benefits and risks. 基于glp -1的可注射药物的微给药、分给药和分给药:平衡潜在的益处和风险。
IF 2.3
Minerva endocrinology Pub Date : 2026-11-13 DOI: 10.23736/S2724-6507.26.04655-5
Marco Infante, Giuseppe Seminara, Andrea Fabbri, Antonio Aversa
{"title":"Microdosing, fractional and split dosing of injectable GLP-1-based drugs: balancing potential benefits and risks.","authors":"Marco Infante, Giuseppe Seminara, Andrea Fabbri, Antonio Aversa","doi":"10.23736/S2724-6507.26.04655-5","DOIUrl":"https://doi.org/10.23736/S2724-6507.26.04655-5","url":null,"abstract":"<p><p>Glucagon-like peptide-1 (GLP-1)-based drugs (also known as incretin receptor agonists) have revolutionized the management of type 2 diabetes and overweight/obesity. Microdosing, fractional dosing and split dosing of GLP-1-based drugs administered by subcutaneous injection (particularly the newer incretin receptor agonists semaglutide and tirzepatide) have recently emerged as alternative off-label dosing strategies used to improve long-term treatment tolerability while preserving or optimizing the therapeutic benefits of these agents. Evidence regarding these practices is mostly anecdotal and their use is not supported by manufacturers, scientific societies, drug regulatory agencies and official clinical guidelines. Fractional dosing of injectable incretin receptor agonists is the off-label administration of injectable GLP-1-based drugs at a fraction of a given standard approved drug dose by counting the audible and tactile clicks generated as the dose selector dial of pre-filled multi-dose injection pens (MDPs) is turned forward (off-label \"click-counting\" method). Microdosing of injectable incretin receptor agonists represents a form of fractional dosing that consists of administering subtherapeutic doses [\"microdoses\": doses lower than the lowest standard approved drug dose (starting dose)] of injectable GLP-1-based drugs with pre-filled MDPs through the \"click-counting\" method. Split dosing of injectable once-weekly incretin receptor agonists consists of administering smaller doses of an injectable once-weekly GLP-1-based drug more frequently than once per week with pre-filled MDPs through the \"click-counting\" method. This Special Article aims to provide a critical appraisal of the potential benefits and risks of microdosing, fractional dosing and split dosing of injectable GLP-1-based drugs, which warrant thorough investigation in future pharmacokinetic/pharmacodynamic studies and clinical trials.</p>","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149408285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improved muscle quality attenuates cardiovascular-kidney-metabolic syndrome risk in non-elderly U.S. adults. 改善肌肉质量可降低非老年美国成年人心血管-肾脏代谢综合征的风险。
IF 2.3
Minerva endocrinology Pub Date : 2026-11-05 DOI: 10.23736/S2724-6507.26.04597-5
Xingyu Yao, Yong Wang
{"title":"Improved muscle quality attenuates cardiovascular-kidney-metabolic syndrome risk in non-elderly U.S. adults.","authors":"Xingyu Yao, Yong Wang","doi":"10.23736/S2724-6507.26.04597-5","DOIUrl":"https://doi.org/10.23736/S2724-6507.26.04597-5","url":null,"abstract":"<p><strong>Background: </strong>Cardiovascular-kidney-metabolic (CKM) syndrome is a newly defined systemic disorder involving complex interactions among cardiovascular, kidney, and metabolic systems. The muscle quality index (MQI) comprehensively assesses skeletal muscle through integrating mass, strength, and function; however, its relationship with CKM syndrome remains unclear, thus limiting the development of muscle quality-based risk assessment and personalized prevention strategies.</p><p><strong>Methods: </strong>We analyzed 1672 adults from National Health and Nutrition Examination Survey (NHANES) 2011-2014. Three MQI parameters were calculated: MQI<inf>arm</inf>, MQI<inf>app</inf>, and MQI<inf>total</inf>. Statistical analyses included logistic regression, subgroup analysis, restricted cubic spline, and advanced machine learning methods.</p><p><strong>Results: </strong>Advanced CKM syndrome participants demonstrated significantly lower MQI values compared to non-CKM and early CKM participants. Logistic regression and restricted cubic spline (RCS) analysis confirmed that higher MQI was inversely associated with the presence of CKM syndrome (P for overall <0.001, P for nonlinear =0.21), with consistent associations across demographic subgroups. Machine learning and Boruta analysis emphasize MQI parameters as a superior discriminatory factor compared to muscle mass or strength alone.</p><p><strong>Conclusions: </strong>MQI demonstrates a significant inverse association with CKM syndrome across various subgroups. Our findings reveal that MQI is a promising, non-invasive indicator for CKM syndrome risk assessment and highlight the significance of improving muscle quality in CKM prevention strategies.</p>","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149334536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Longitudinal effects of gender-affirming hormone therapy on pain, fatigue, and central sensitization-related disorders in individuals with gender dysphoria. 性别确认激素治疗对性别焦虑症患者疼痛、疲劳和中枢敏化相关疾病的纵向影响。
IF 2.3
Minerva endocrinology Pub Date : 2026-10-29 DOI: 10.23736/S2724-6507.26.04573-2
Lala Soltanova, Emre Durcan, Banu B Kocaman, Ilkin Muradov, Sabriye S Taze, Rana Terlemez, Serdar Sahin, Deniz Palamar, Senol Turan, Pinar Kadioglu
{"title":"Longitudinal effects of gender-affirming hormone therapy on pain, fatigue, and central sensitization-related disorders in individuals with gender dysphoria.","authors":"Lala Soltanova, Emre Durcan, Banu B Kocaman, Ilkin Muradov, Sabriye S Taze, Rana Terlemez, Serdar Sahin, Deniz Palamar, Senol Turan, Pinar Kadioglu","doi":"10.23736/S2724-6507.26.04573-2","DOIUrl":"https://doi.org/10.23736/S2724-6507.26.04573-2","url":null,"abstract":"<p><strong>Background: </strong>Gender-affirming hormone therapy (GAHT) is an essential component of care for individuals with gender dysphoria (GD), aiming to relieve psychological distress and improve overall well-being. Chronic pain, fatigue, and disorders associated with central sensitization syndrome (CSS) including fibromyalgia and chronic fatigue are more prevalent in cisgender female than in male, suggesting a modulatory role of sex hormones, particularly estrogen, in pain processing. This study aimed to examine the effects of one year of GAHT on symptoms related to CSS in individuals with GD and to explore whether estrogen or testosterone exposure differently influences pain sensitivity.</p><p><strong>Methods: </strong>In this 12-month prospective study, 47 individuals with GD (37 assigned female at birth [AFAB], 10 assigned male at birth [AMAB]) were evaluated before and after initiation of GAHT. Mood, fatigue, fibromyalgia, and central sensitization were assessed using validated instruments, including the Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), Fatigue Impact Scale (FIS), Fatigue Severity Scale (FSS), Fibromyalgia Survey Diagnostic Criteria and Severity Scale (FSDC), and Central Sensitization Inventory (CSI).</p><p><strong>Results: </strong>A total of 47 participants completed the study (AFAB: N.=37; AMAB: N.=10). In AFAB participants, depressive symptoms decreased significantly after 1 year of GAHT (BDI: 6 [3-13] vs. 2 [0.5-7.5], P=0.002), while anxiety levels remained unchanged (P=0.087). Fatigue impact improved (FIS: 55 [40.5-76.5] vs. 46 [42-61], P=0.017), with significant reductions in physical (P=0.005) and social domains (P=0.043), but not cognitive fatigue (P=0.075). Fibromyalgia-related measures showed stable WPI (P=0.337) and PSD scores (P=0.120), whereas symptom severity (SS) increased (P=0.017). CSI scores did not change significantly (P=0.163). In AMAB participants, no significant changes were observed in depression, anxiety, fatigue, fibromyalgia-related scores, or CSI (all P>0.05).</p><p><strong>Conclusions: </strong>In this study, GAHT was associated with improvements in depressive symptoms but was not associated with significant changes in pain sensitivity or central sensitization measures. Estrogen exposure in AMAB and testosterone therapy in AFAB participants did not lead to measurable changes in CSS-related symptom burden during the follow-up period. However, given the relatively small sample size, these findings should be considered preliminary and require confirmation in larger prospective studies.</p>","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149298799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
18F-Fluoro-L-dihydroxyphenylalanine positron emission tomography in the initial staging of medullary thyroid carcinoma. 18f -氟- l -二羟基苯丙氨酸正电子发射断层扫描在甲状腺髓样癌初始分期中的应用。
IF 2.3
Minerva endocrinology Pub Date : 2026-10-29 DOI: 10.23736/S2724-6507.26.04586-0
Alessio Imperiale, Domenico Albano, Arnoldo Piccardo, Gaetano Paone, Morgan Huon, David Taïeb, Giorgio Treglia
{"title":"18F-Fluoro-L-dihydroxyphenylalanine positron emission tomography in the initial staging of medullary thyroid carcinoma.","authors":"Alessio Imperiale, Domenico Albano, Arnoldo Piccardo, Gaetano Paone, Morgan Huon, David Taïeb, Giorgio Treglia","doi":"10.23736/S2724-6507.26.04586-0","DOIUrl":"https://doi.org/10.23736/S2724-6507.26.04586-0","url":null,"abstract":"<p><strong>Background: </strong>Accurate initial staging of medullary thyroid carcinoma (MTC) is critical for surgical planning and long-term outcome. While <sup>18</sup>F-Fluorodihydroxyphenylalanine Positron Emission Tomography/Computed Tomography (<sup>18</sup>F-DOPA PET/CT) is well established in the detection of recurrent disease, its role in the preoperative setting remains unclear. This review aimed to evaluate the diagnostic performance and clinical relevance of <sup>18</sup>F-DOPA PET/CT in the initial staging of MTC.</p><p><strong>Methods: </strong>A systematic literature search was performed to identify studies assessing <sup>18</sup>F-DOPA PET/CT in treatment-naïve MTC patients. Four studies met the inclusion criteria and were qualitatively analyzed. Data were synthesized focusing on compartment-specific performance, tumor burden, and potential impact on clinical management.</p><p><strong>Results: </strong><sup>18</sup>F-DOPA PET/CT demonstrated good sensitivity for primary tumor detection (86-88%), although performance was limited in microcarcinomas. A marked heterogeneity emerged across anatomical compartments. Sensitivity for central lymph node metastases was consistently low (28-53%), whereas higher values were observed in the lateral neck (57-81%), with high specificity when reported. Diagnostic performance was strongly influenced by tumor burden, with significantly reduced sensitivity in low-volume disease and improved detection in patients with more extensive nodal involvement. The integration of biochemical markers further supported a burden-dependent behavior, with higher calcitonin levels associated with improved imaging performance. In distant staging, <sup>18</sup>F-DOPA PET/CT identified metastatic disease in a subset of patients but showed limited sensitivity for small hepatic lesions compared with dedicated MRI. Importantly, improvements in lesion detection did not consistently translate into meaningful changes in surgical management.</p><p><strong>Conclusions: </strong>The role of <sup>18</sup>F-DOPA PET/CT in the initial staging of MTC is selective and context-dependent. While it may provide incremental value in patients with higher tumor burden or suspected lateral nodal disease, its limited sensitivity in the central compartment and in low-volume disease prevents its use as a standalone staging modality. Therefore, <sup>18</sup>F-DOPA PET/CT should be considered a context-driven adjunct rather than a routine tool, to be integrated within a multimodal imaging strategy rather than used as a standalone staging modality.</p>","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149298796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypothalamus-pituitary-adrenocortical responses to critical illness: new insights with clinical implications. 下丘脑-垂体-肾上腺皮质对危重疾病的反应:具有临床意义的新见解。
IF 2.3
Minerva endocrinology Pub Date : 2026-10-23 DOI: 10.23736/S2724-6507.26.04546-X
Gabriel Marzari, Angeliki-Argyri Savvopoulou-Tzakopoulou, Lauren DE Bruyn, Lies Langouche, Greet VAN DEN Berghe
{"title":"Hypothalamus-pituitary-adrenocortical responses to critical illness: new insights with clinical implications.","authors":"Gabriel Marzari, Angeliki-Argyri Savvopoulou-Tzakopoulou, Lauren DE Bruyn, Lies Langouche, Greet VAN DEN Berghe","doi":"10.23736/S2724-6507.26.04546-X","DOIUrl":"https://doi.org/10.23736/S2724-6507.26.04546-X","url":null,"abstract":"<p><p>Critical illness profoundly affects the hypothalamus-pituitary-adrenocortical (HPA) axis. In the acute phase of sepsis and other critical conditions, systemic cortisol levels rise markedly, yet circulating ACTH is low. Peripheral adaptations - reduced cortisol metabolism, decreased cortisol-binding proteins, and tissue-specific modulation of glucocorticoid receptor signaling - rather than sustained central HPA axis activation generate compartmentalized increased cortisol actions. As illness persists beyond one week, patients transition into prolonged critical illness characterized by a central HPA suppression, impaired adrenocortical structure and function, together increasing the risk for ICU-acquired adrenal insufficiency beyond 4 weeks. Although glucocorticoids, in stress doses, remain widely used for shock reversal, they exacerbate this HPA suppression and aggravate acute and long-term complications of critical illness. A better mechanistic understanding is essential to guide targeted and adequately dosed therapies.</p>","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149270722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Age and tumor size interact to increase the risk of incomplete response to therapy in differentiated thyroid carcinoma. 年龄和肿瘤大小相互作用增加分化型甲状腺癌治疗不完全反应的风险。
IF 2.3
Minerva endocrinology Pub Date : 2026-10-23 DOI: 10.23736/S2724-6507.26.04516-1
Shaza Ahmed Samargandy, Saad Samargandy
{"title":"Age and tumor size interact to increase the risk of incomplete response to therapy in differentiated thyroid carcinoma.","authors":"Shaza Ahmed Samargandy, Saad Samargandy","doi":"10.23736/S2724-6507.26.04516-1","DOIUrl":"https://doi.org/10.23736/S2724-6507.26.04516-1","url":null,"abstract":"<p><strong>Background: </strong>This study evaluates whether age modifies the association between tumor size and the risk of incomplete response to therapy (IRT) in patients with differentiated thyroid cancer (DTC).</p><p><strong>Methods: </strong>A retrospective cohort study that included patients with DTC who underwent thyroidectomy from 2018 to 2022. Clinical outcomes were based on the 2015 ATA response to therapy classification, with the study outcome defined as biochemical or structural IRT. The cutoffs for age and tumor size were 55 years and 2 cm, respectively. We tested the interaction between age and tumor size on the risk of IRT using logistic regression models adjusted for aggressive histological factors.</p><p><strong>Results: </strong>There were 232 patients included, with a mean age of 41.3 years and a median follow-up of 4.0 years. There were 39 patients (17%) who were 55 years and older, and 118 (51%) patients who had a tumor size of >2 cm. There were 54 (23%) patients with IRT. Age modified the association between tumor size and IRT (P value for interaction=0.03), such that the IRT OR (95% CI) for age ≥55 years in patients with tumor size ≤2 cm was 0.56 (0.06, 4.87). While in patients ≥55 years of age with tumor size >2 cm, it was 7.54 (2.25, 25.31). Tumor size >2 cm in patients <55 years had OR=1.53 (0.65, 3.60).</p><p><strong>Conclusions: </strong>In tumors ≤2cm in size, age did not affect the risk of IRT, but when the size is >2cm, advanced age is associated with a higher risk of IRT.</p>","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149270746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Uncomplicated diabetes and adverse in-hospital outcomes in tumor lysis syndrome: a national cohort analysis. 肿瘤溶解综合征的无并发症糖尿病和不良住院结果:一项国家队列分析。
IF 2.3
Minerva endocrinology Pub Date : 2026-09-01 Epub Date: 2026-05-12 DOI: 10.23736/S2724-6507.26.04552-5
Fiqe Khan, Aamir S Javed, Meher Ayyazuddin, Abdullah Ahmad
{"title":"Uncomplicated diabetes and adverse in-hospital outcomes in tumor lysis syndrome: a national cohort analysis.","authors":"Fiqe Khan, Aamir S Javed, Meher Ayyazuddin, Abdullah Ahmad","doi":"10.23736/S2724-6507.26.04552-5","DOIUrl":"10.23736/S2724-6507.26.04552-5","url":null,"abstract":"","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":"339-343"},"PeriodicalIF":2.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147874855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A review of survodutide: a new dual acting agonist. 一种新的双作用激动剂——生存肽的研究进展。
IF 2.3
Minerva endocrinology Pub Date : 2026-09-01 Epub Date: 2026-03-19 DOI: 10.23736/S2724-6507.26.04406-4
Meenakshi R Yathindra, Ayush Bhattacharjee, Nikhil Pundir, Pooja Patel, Nidhi E Jacob, Preeti E Jossy, Rajmohan Seetharaman
{"title":"A review of survodutide: a new dual acting agonist.","authors":"Meenakshi R Yathindra, Ayush Bhattacharjee, Nikhil Pundir, Pooja Patel, Nidhi E Jacob, Preeti E Jossy, Rajmohan Seetharaman","doi":"10.23736/S2724-6507.26.04406-4","DOIUrl":"10.23736/S2724-6507.26.04406-4","url":null,"abstract":"<p><p>Survodutide represents an innovative approach to obesity management and metabolic-associated fatty liver disease (MAFLD). These conditions, often closely linked with type 2 diabetes (T2DM) and cardiovascular diseases, demand effective treatment strategies. Survodutide acts by targeting both GLP-1 and glucagon receptors. This new dual agonist offers potential transformative benefits, with early clinical trials showcasing significant weight loss and improvements in metabolic markers. Survodutide's mechanism of action includes appetite regulation, enhanced glucose metabolism, and increased energy expenditure, making it a promising option for those struggling with obesity and related health issues. This review assesses Survodutide's pharmacology, efficacy, and safety in MASH and obesity, while also outlining its broader metabolic and cardiovascular benefits. It compares Survodutide's dual-agonist mechanism and clinical performance with single-target incretin therapies to clarify its potential role in the evolving treatment landscape. While the initial results are promising, the review emphasizes the importance of continued research to fully understand Survodutide's long-term safety and effectiveness. Ongoing trials will provide critical insights into its overall impact, side effects, patient response, and cost considerations. This article highlights Survodutide's potential in the treatment of obesity and metabolic disordersand evaluates its place in therapy for seeking improved outcomes.</p>","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":"306-321"},"PeriodicalIF":2.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147486776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of oral semaglutide as add-on therapy in poorly controlled type 2 diabetes on background SGLT2 inhibitors: a real-world, multi-center, retrospective, observational study (RYS2). 口服西马鲁肽作为SGLT2抑制剂治疗控制不佳的2型糖尿病的疗效和安全性:一项真实世界、多中心、回顾性、观察性研究(RYS2)
IF 2.3
Minerva endocrinology Pub Date : 2026-09-01 Epub Date: 2025-11-27 DOI: 10.23736/S2724-6507.25.04376-3
Maria E Malighetti, Fabio Vescini, Maria Carpentieri, Anna Altomari, Federica Turchi, Andrea DA Porto, Marco Dauriz
{"title":"Efficacy and safety of oral semaglutide as add-on therapy in poorly controlled type 2 diabetes on background SGLT2 inhibitors: a real-world, multi-center, retrospective, observational study (RYS2).","authors":"Maria E Malighetti, Fabio Vescini, Maria Carpentieri, Anna Altomari, Federica Turchi, Andrea DA Porto, Marco Dauriz","doi":"10.23736/S2724-6507.25.04376-3","DOIUrl":"10.23736/S2724-6507.25.04376-3","url":null,"abstract":"<p><strong>Background: </strong>Treatment of type 2 diabetes mellitus (T2DM) relies on diverse glucose-lowering medications, championing sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists as viable options to address concurrent cardiovascular risk. An oral formulation of semaglutide (Rybelsus<sup>®</sup>, Novo Nordisk) has been recently introduced to clinical use for managing T2DM. Accordingly, there is a paucity of practice evidence while building experience on its combination with SGLT2i.</p><p><strong>Methods: </strong>In this observational, single-arm, retrospective study, data collected from 142 T2DM patients (66% males, 68% older than 60 years, 85% overweight/obese) treated with oral semaglutide in combination with SGLT2i were analyzed.</p><p><strong>Results: </strong>After 6.8±2.6 months of treatment, both glycosylated hemoglobin (HbA1c) and fasting plasma glucose levels significantly improved: 39.6% of patients achieved HbA1c<inf>DCCT</inf> ≤7% (HbA1c<inf>IFCC</inf> ≤53.0 mmol/mol) and 18.8% experienced both a decrease of HbA1c ≥1% and a weight loss ≥5%. In addition, body weight, body mass index, waist circumference, triglycerides, and total cholesterol levels were significantly reduced. Regarding safety, 94.7% of reported adverse events were non-serious gastrointestinal symptoms and 1 patient experienced hypoglycemia.</p><p><strong>Conclusions: </strong>The herein presented real-world data suggest that oral semaglutide can be regarded as safe and effective, when used as add-on medication for uncontrolled T2DM on background SGLT2i.</p>","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":"248-256"},"PeriodicalIF":2.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145636169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genomic mapping of diabetic kidney disease biomarkers and identification of potential inhibitors through virtual screening. 糖尿病肾病生物标志物的基因组定位和通过虚拟筛选鉴定潜在抑制剂。
IF 2.3
Minerva endocrinology Pub Date : 2026-09-01 Epub Date: 2025-10-21 DOI: 10.23736/S2724-6507.25.04399-4
Yi Liu, Yu Wang
{"title":"Genomic mapping of diabetic kidney disease biomarkers and identification of potential inhibitors through virtual screening.","authors":"Yi Liu, Yu Wang","doi":"10.23736/S2724-6507.25.04399-4","DOIUrl":"10.23736/S2724-6507.25.04399-4","url":null,"abstract":"<p><strong>Background: </strong>Diabetic kidney disease (DKD) is a common and serious complication of diabetes mellitus, marked by a multifactorial pathogenesis and the absence of sensitive diagnostic biomarkers. Identifying novel molecular targets and therapeutic options is essential to improve early diagnosis and treatment outcomes.</p><p><strong>Methods: </strong>To uncover potential biomarkers and therapeutic candidates, we performed an integrated genomic analysis using microarray and RNA-seq datasets from the Gene Expression Omnibus (GEO) and Sequence Read Archive (SRA) databases. Differentially expressed genes (DEGs) were identified and subjected to protein-protein interaction (PPI) network analysis. Key genes were further explored through virtual screening of an FDA-approved compound library using molecular docking techniques. Drug-likeness was assessed via Lipinski's rule of five.</p><p><strong>Results: </strong>A total of 40 DEGs were identified, among which ISCU (downregulated; involved in iron-sulfur cluster biogenesis) and AP1S2 (upregulated; associated with vesicular trafficking) emerged as potential biomarkers. PPI analysis revealed their involvement in critical DKD-related pathways, such as extracellular matrix remodeling and oxidative stress. Virtual screening identified six FDA-approved compounds with high binding affinity (≤-7.96 kcal/mol) to ISCU, notably ZINC000001576020, all of which complied with Lipinski's rule.</p><p><strong>Conclusions: </strong>This in-silico study nominates ISCU and AP1S2 as candidate diagnostic biomarkers for DKD and identifies computationally prioritized inhibitors targeting ISCU. These findings require experimental validation but provide a molecular framework for precision diagnosis and therapeutic development. These findings offer new molecular insights that could inform precision diagnosis and personalized treatment strategies for diabetic kidney disease.</p>","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":" ","pages":"266-277"},"PeriodicalIF":2.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145337313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书